The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 61,183 | 3,399,034 | SH | SOLE | 3,399,034 | 0 | 0 | ||
| Cue Health Inc. | COM | 229790100 | 11,882 | 1,006,089 | SH | SOLE | 1,006,089 | 0 | 0 | ||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 6,523 | 1,787,094 | SH | SOLE | 1,787,094 | 0 | 0 | ||
| Decibel Therapeutics, Inc. | COM | 24343R106 | 2,295 | 297,711 | SH | SOLE | 297,711 | 0 | 0 | ||
| Kinnate Biopharma Inc. | COM | 49705R105 | 222,641 | 9,671,643 | SH | SOLE | 9,671,643 | 0 | 0 | ||
| Kura Oncology, Inc. | COM | 50127T109 | 34,650 | 1,849,947 | SH | SOLE | 1,849,947 | 0 | 0 | ||
| Lyell Immunopharma, Inc. | COM | 55083R104 | 196,576 | 13,282,181 | SH | SOLE | 13,282,181 | 0 | 0 | ||
| Nurix Therapeutics, Inc. | COM | 67080M103 | 36,126 | 1,205,798 | SH | SOLE | 1,205,798 | 0 | 0 | ||
| Olema Pharmaceuticals, Inc. | COM | 68062P106 | 9,426 | 342,030 | SH | SOLE | 342,030 | 0 | 0 | ||
| Pharvaris N.V. | COM | N69605108 | 57,834 | 3,261,926 | SH | SOLE | 3,261,926 | 0 | 0 | ||
| Quantum-Si Incorporated | COM CL A | 74765K105 | 37,227 | 4,463,619 | SH | SOLE | 4,463,619 | 0 | 0 | ||
| Tempest Therapeutics, Inc. | COM | 87978U108 | 2,752 | 190,213 | SH | SOLE | 190,213 | 0 | 0 | ||